Subcritical fluid and molecular distillation extraction of Nannochloropsis gaditana lipid and its metabolic benefits in hyperlipidemic mice

The marine microalga Nannochloropsis gaditana is a fast-growing species rich in long-chain polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA), and other bioactive compounds. In this study, lipids from N. gaditana powder were extracted and refined using subcritical butane c...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruilong Meng, Yu Zhang, Yishan Jiang, Bin Li, Xi Chen, Zhongliang Sun, Liqin Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Nutrition
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnut.2025.1615332/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The marine microalga Nannochloropsis gaditana is a fast-growing species rich in long-chain polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA), and other bioactive compounds. In this study, lipids from N. gaditana powder were extracted and refined using subcritical butane combined with molecular distillation to obtain a highly purified lipid extract with increased EPA concentration (58.92% w/w) and improved biological activity. The anti-hyperlipidemic effects of the lipid extract were evaluated in female Kunming mice (4 weeks old) fed a high-fat diet. Results demonstrated that N. gaditana lipid supplementation significantly reduced body weight gain, serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), while elevating high-density lipoprotein cholesterol (HDL-C). Additionally, the lipid extract ameliorated hepatic inflammation (reduced TNF-α and IL-1β levels), attenuated oxidative stress (enhanced SOD, CAT, and GSH-Px activities), and modulated lipid metabolism enzymes (inhibited FAS, ACC, and HMGCR; upregulated LCAT). These findings highlight the potential of EPA-rich N. gaditana lipid as a natural and sustainable therapeutic strategy for managing hyperlipidemia and associated metabolic disorders.
ISSN:2296-861X